AMIX Autonomix Medical, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1617867 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY29.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-176.0%
ROA-146.1%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets15.3%
Debt / equity0.00x
Current ratio6.52x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio2.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0 | $0 | $0 | $0 |
| R&D expense | $7.14M | $4.72M | $2.23M | $745,000 |
| SG&A expense | $9.89M | $6.86M | $5.25M | $1.25M |
| Operating income | -$17.03M | -$11.59M | -$12.03M | -$1.99M |
| Interest expense | $0 | $176,000 | $79,000 | $0 |
| Pretax income | -$16.71M | -$11.41M | -$15.43M | -$1.99M |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$16.71M | -$11.41M | -$15.43M | -$1.99M |
| EBITDA | -$17.02M | -$11.40M | -$11.95M | -$1.99M |
| EPS (basic) | -2.32 | -6.46 | -14.82 | -0.17 |
| EPS (diluted) | — | — | — | — |
| Balance sheet | ||||
| Cash & equivalents | $7.00M | $9.14M | $8.61M | $865,000 |
| Current assets | $7.58M | $9.61M | $9.39M | $865,000 |
| PP&E, net | $19,000 | $21,000 | $16,000 | $0 |
| Total assets | $7.60M | $9.81M | $9.41M | $865,000 |
| Current liabilities | $1.71M | $1.71M | $777,000 | $221,000 |
| Short-term debt | — | — | $0 | — |
| Long-term debt | — | — | — | $0 |
| Total debt | — | — | — | $0 |
| Total liabilities | $1.71M | $1.71M | $1.78M | $221,000 |
| Shareholders' equity | $5.89M | $8.10M | $7.63M | $644,000 |
| Net debt | — | — | — | -$865,000 |
| Shares outstanding | 542,312 | 2.50M | 942,575 | 12.34M |
| Cash flow statement | ||||
| Operating cash flow | -$12.28M | -$8.26M | -$6.60M | -$1.85M |
| Capital expenditure | $10,000 | $14,000 | $19,000 | $0 |
| Free cash flow | -$12.29M | -$8.27M | -$6.62M | -$1.85M |
| Investing cash flow | -$10,000 | -$14,000 | -$19,000 | $0 |
| Financing cash flow | $10.16M | $8.80M | $14.41M | $675,000 |
| Depreciation & amortization | $12,000 | $183,000 | $81,000 | $0 |
| Stock-based compensation | $529,000 | $1.63M | $618,000 | $0 |
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.